Mary Jo Laffler
Executive Editor, US Commercial/R&D
Mary Jo oversees a talented team analyzing business and clinical activity for Scrip, Pink Sheet and In Vivo. Since starting as a reporter in 2000, Mary Jo has held editor positions across Pink Sheet and the former Pink Sheet DAILY and Pharmaceutical Approvals Monthly, and covered the drug development process from clinical trials to FDA review to approval and launch, as well as keeping track of broad industry trends and the commercial landscape. Mary Jo helped create the FDA Performance Tracker charts as a way to use regulatory data to aid development decisions and better understand agency patterns, and continues to enjoy working with data to identify industry trends through features and infographics. She frequently moderates webinars and panels at conferences. An avid reader, Mary Jo volunteers as a literacy tutor and is on the board of the local library.
Latest From Mary Jo Laffler
With slower than expected sales of some newer products, Bristol lowered mid-term guidance for its new product portfolio and extended the timeline for reaching the goal to 2026.
The US FDA granted an accelerated approval to Sarepta’s Elevidys, the first gene therapy to be approved for some children with Duchenne muscular dystrophy.
The deadline is approaching for submissions to the 2023 Citeline Awards; gain recognition for your clinical research team, real world evidence project, diversity and inclusion efforts, and more.
Pharma will partner with SyntheX on targeted protein degradation, with Autolus on cell therapy safety. Novo Nordisk gets rights to Ventus’s lead compound in NASH and chronic kidney disease.
Specialty pharma Neuraxpharm is taking on 38 mature brands from Sanofi, in CNS, pain and vascular diseases. Lilly is working with Triastek on 3D printing technology for targeted release of drugs in specific regions of the gastrointestinal tract.
Biogen caught a lucky break in getting the first FDA approval for a potentially disease-modifying Alzheimer’s therapy, but doubt over clinical benefit and commercial missteps have left Biogen in a precarious position a year later.